Vance Fowler, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Debiopharm
    Topic:
    staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/12/2025
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    GSK, Genentech
    Topic:
    Staph aureus
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/11/2025
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Valanbio
    Topic:
    bacteria
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/21/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    ArcBio
    Topic:
    diagnostics
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    07/11/2023
  • Attribution:
    Self
    Type of financial relationship:
    Patent
    Ineligible company:
    Patent pending
    Topic:
    diagnostics
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/29/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    UpToDate
    Topic:
    Royalties
    Date added:
    02/20/2024
    Date updated:
    02/20/2024
    Relationship end date:
    02/24/2027

Pages

Return to 2024 Inova Fairfax MGR (Enduring Material): Update in S. aureus Bacteremia